Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Commentary on: OpenUrlCrossRefPubMedWeb of Science
In 2005, the US Preventive Services Task Force (USPSTF) updated its 2002 hormone replacement therapy recommendations, advising against the routine use of oestrogen and progestin (E+P) and unopposed oestrogen (E) to prevent chronic conditions in menopausal women. Menopausal hormone therapy (MHT) had been commonly prescribed to prevent conditions such as cardiovascular disease, dementia and osteoporosis. Clinical trial data dramatically changed clinical practice. The Heart and Estrogen/Progestin Replacement Study (HERS) examined conjugated equine oestrogen (CEE)+medroxyprogesterone acetate in women with coronary disease; hormone therapy did not decrease coronary events. Primary prevention was studied in the Women's Health Initiative (WHI) trial: E+P or E in women with …
Competing interests None.